CEO maligns FDA delays over depression device treatments’ US market entry
The CEO of Flow Neuroscience has called out the US Food and Drug Administration (FDA) for market entry delays for clinically validated devices for treating depression. The post CEO maligns FDA delays over depression device treatments’ US market entry appeared first on Medical Device Network.
The CEO of Flow Neuroscience has called out the US Food and Drug Administration (FDA) for market entry delays for clinically validated devices for treating depression.
The post CEO maligns FDA delays over depression device treatments’ US market entry appeared first on Medical Device Network.
